WNT5A and malignant colon neoplasm: Consistent with this, it has been reported recently [24] that using Wnt3a and Wnt5a as prototype ligands to activate the canonical or the non-canonical pathways, respectively, in colon cancer stem cells (CSCs), both ligands promote sphere-formation capacity and proliferation in a β-catenin-independent manner.